Prostaglandins F, Synthetic
"Prostaglandins F, Synthetic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Analogs or derivatives of prostaglandins F that do not occur naturally in the body. They do not include the product of the chemical synthesis of hormonal PGF.
| Descriptor ID |
D011461
|
| MeSH Number(s) |
D10.251.355.255.550.775.500 D23.469.050.175.725.775.500 D23.469.700.670
|
| Concept/Terms |
Prostaglandins F, Synthetic- Prostaglandins F, Synthetic
- PGF Synthetic
- Synthetic, PGF
- Prostaglandin F Analogues
- Analogues, Prostaglandin F
- Prostaglandin F Analogs
- Analogs, Prostaglandin F
- Synthetic Prostaglandins F
|
Below are MeSH descriptors whose meaning is more general than "Prostaglandins F, Synthetic".
Below are MeSH descriptors whose meaning is more specific than "Prostaglandins F, Synthetic".
This graph shows the total number of publications written about "Prostaglandins F, Synthetic" by people in this website by year, and whether "Prostaglandins F, Synthetic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 3 | 0 | 3 |
| 2009 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prostaglandins F, Synthetic" by people in Profiles.
-
Soltani G, Shalaby WS, Razeghinejad R. Latanoprostene bunod: the first nitric oxide-donating antiglaucoma medication. Med Gas Res. 2025 Jun 01; 15(2):220-227.
-
Wong JC, Shiuey EJ, Razeghinejad R, Shukla AG, Kolomeyer NN, Myers JS, Pro MJ, Lee D. The effectiveness and tolerability of fixed-dose combination netarsudil 0.02%/latanoprost 0.005% at a tertiary glaucoma center. Graefes Arch Clin Exp Ophthalmol. 2023 Jan; 261(1):193-200.
-
Ostler E, Rhee D, Burney E, Sozeri Y. Advances in medical therapy for glaucoma. Curr Opin Ophthalmol. 2021 Mar 01; 32(2):129-133.
-
Mehran NA, Sinha S, Razeghinejad R. New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. Eye (Lond). 2020 01; 34(1):72-88.
-
Rabinowitz MP, Katz LJ, Moster MR, Myers JS, Pro MJ, Spaeth GL, Sharma P, Stefanyszyn MA. Unilateral Prostaglandin-Associated Periorbitopathy: A Syndrome Involving Upper Eyelid Retraction Distinguishable From the Aging Sunken Eyelid. Ophthalmic Plast Reconstr Surg. 2015 Sep-Oct; 31(5):373-8.
-
Shah M, Lee G, Lefebvre DR, Kronberg B, Loomis S, Brauner SC, Turalba A, Rhee DJ, Freitag SK, Pasquale LR. A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features. PLoS One. 2013; 8(5):e61638.
-
Ichhpujani P, Katz LJ, Hollo G, Shields CL, Shields JA, Marr B, Eagle R, Alvim H, Wizov SS, Acheampong A, Chen J, Wheeler LA. Comparison of human ocular distribution of bimatoprost and latanoprost. J Ocul Pharmacol Ther. 2012 Apr; 28(2):134-45.
-
Jay Katz L, Myers JS. Smoothing the intraocular pressure roller coaster: a new goal? Am J Ophthalmol. 2009 Aug; 148(2):177-8.
-
Ooi YH, Oh DJ, Rhee DJ. Effect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cells. Invest Ophthalmol Vis Sci. 2009 Nov; 50(11):5259-65.
-
Spaeth GL. Allergic contact dermatitis caused by topical eye drops. Am J Ophthalmol. 2006 Oct; 142(4):706.